


INBRIJA® PRESCRIPTION REQUEST FORM

Fax completed form to: 1 855-886-2484





PLEASE COMPLETE ALL FIELDS TO AVOID ANY DELAYS IN PROCESSING.

				I LLAGE	DOWN ELTE ALL	TILLEDO IC	D AVOID AIN	DELAIS IN 11		4.				
	PA	TIENT	INFORM	ATION					PRESC	RIBER INFO	RMATION			
First Name MI			Last Name				Prescribe	Prescriber First and Last Name NPI				# DEA #		
1	Last 4 Digits of SSN		DOB (mm/dd	/yyyy)			Specialty	: Neurology	Other (Please specify):				
M F							Practice N	lame	Phone		Ext F	ax		
Address (No PO Box														
							Address							
City			State	Zip	Zip									
							City			State	Zip			
Preferred Phone		Phone	Typo											
T TOTOTT CO T TIONE		1	lome Cell	Work	Office Cor	ntact Name		Contact Phone			Ext			
	Tionic odi			WUIK										
Alternate Phone E			mail				Contact F	ax		Email				
	INICI	IDVNC	E INFORI	MATION						PRESCRIPTI	ON			
Diagram samu tha fo					in alouda	Laws governing prescriptions vary from state to state. Please observe your state's requirements.								
riease copy the it with fax.	ONT AND DACK OF THE	prescri	otion arug an	a meaicai in	surance cards and	inciuae	1 -	PLEASE SELECT	-			-		
Prescription Dr	rug Insurance	F	Patient Has NO	Prescription	Drug Insurance									
Prescription Insurer Name Phone							Ma	intenance Prescri	iption:					
							1 '	Rx: Inbrija 42 mg capsules						
ID #	BIN#		PCN# Group #					y inhale contents of a o exceed 5 doses a		lmg) as needed, t	or symptoms o	f an OFF period	•	
ID #	DIIV#		FUN	 	Group #		11000	0 0,0000 0 0,0000 0	uuy.					
							Dispense	:	Number of ca	rtons Refills:				
Medical Insura	nce	F	Patient has NO	Medical Insu	rance			1 Carton = 1 Inhal	er + 60 capsu	les (treats 30 OFF	periods)			
Primary Medical Insurance Cardholder Name								ICD-10 Diagnosis:			Allergies:			
,								Parkinson's Disease			7 in or groot.			
2 1 1 1 0	ID #				020	raikiiisuiis disease								
Relationship to Cardholder Self Spouse Child Other Group #			ID #				Othe	er Diagnosis Code						
							Patient is taking concomitant carbidopa/levodopa regimen. Y N							
			Phone				Patient is	taking concomitant	carbidopa/ievo	dopa regimen.		,	Y N	
								currently taking or wi			n non-selective	MAO	Y N	
Secondary Medical	Cardholder Name				inhibitor (e	e.g., phenelzine and t	ranylcypromin	e).						
							Patient ha	s asthma, COPD, or	chronic under	lying lung diseas	е.	`	Y N	
Relationship to Card	tholder		ID#						DDECCD	IBER AUTH	ADIZATION	ı		
Self Spor		Other	10 #						PNESCH	IDEN AUTH	UNIZATIUI	V		
оси ори	use Cilliu	Ouici						I certify that this therapy is medically necessary and that this is accurate to the best of my knowledge.						
Group #			Phone				I authorize Acorda Therapeutics, Inc. and the entities that operate its patient support hub, Prescription Support Services (collectively, "Acorda"), to use and disclose the patient information herein contained to							
								ent's insurers and pl						
	РАТ	IFNT /	AUTHORIZ	ATION			,	ned in 45 CFR § 160 ng as well as the pat	**				*	
								in a manner consi				, ,		
	r Marketing Materia							the patient to repor						
_	ree to the <i>Patient Au</i>							ce programs offered support the patient's						
Patient or Gua	ırdıan/Legal Represer	ntative Sig	gnature <i>(Sign</i> a	ature and da	ate required for serv	rices)		rescription to the pha		, , , , , , , , , , , , , , , , , , , ,	,			
<u> </u>							Pres	criber Signature (Ma	anuai signatu	ire and date req	uired)			
Print Name					Date									
							Dian	ense as Written				Date		
Initial Here	The sinest !	-1 1				A	DISP	onot ao Wiilleli		OR .		Date		
					cription Support Servance coverage, and S					vn				
					(participation optional)									
Initial Here The signature above also denotes that I have read and agree to the Patient														
Marketing Consent on page 3 (participation optional).							Sub	stitution Permissible				Date		



INBRIJA® PRESCRIPTION REQUEST FORM

Fax completed form to: 1 855-886-2484

For assistance please call Prescription Support Services at: 1 888-887-3447

Indication

INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) treated with carbidopa/levodopa.

Important Safety Information

- INBRIJA is contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to risk of hypertension. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.
- Patients treated with levodopa, the active ingredient in INBRIJA, have
 reported falling asleep during activities of daily living, including operation of
 motor vehicles, which sometimes resulted in accidents. Many patients
 reported somnolence but some reported no warning signs (sleep attack).
 This may occur more than a year after initiating treatment. Reassess patients
 for drowsiness/sleepiness including occurrence during specific activities.
 Advise patients of potential for drowsiness and ask about factors that may
 increase this risk (e.g., sedating medications, sleep disorders).
 - Consider discontinuing INBRIJA in patients who report significant
 daytime sleepiness or falling asleep during activities that require active
 participation. If continuing INBRIJA, advise patients not to drive and to
 avoid activities that may result in harm. There is insufficient information
 that dose reduction will eliminate episodes of falling asleep during
 activities of daily living.
- Neuroleptic malignant syndrome-like symptoms (e.g., elevated temperature, muscular rigidity, altered consciousness, autonomic instability) have been reported with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy.
- Hallucinations (with or without confusion, insomnia, and excessive dreaming)
 may occur and may respond to reducing levodopa therapy. Abnormal
 thinking and behavior may present with paranoid ideation, delusions,
 hallucinations, confusion, psychotic-like behavior, disorientation, aggressive
 behavior, agitation, and delirium.
- INBRIJA should ordinarily not be used in patients with major psychotic disorder due to risk of exacerbating psychosis. Dopamine antagonists used to treat psychosis may exacerbate symptoms of PD and may decrease INBRIJA efficacy.
- Patients on medications that increase central dopaminergic tone such as INBRIJA can experience intense urges to gamble or spend money, increased sexual urges, binge eating, and/or other intense urges, and inability to control

them. In some cases, these urges stopped with dose reduction or medication discontinuation. Since some patients may not recognize these behaviors as abnormal, ask patients or their caregivers about development of new or increased urges and consider stopping INBRIJA if this occurs.

- INBRIJA may cause or exacerbate dyskinesias. If troublesome dyskinesias occur, consider stopping INBRIJA or adjusting other PD medications.
- INBRIJA is not recommended in patients with asthma, COPD, or other chronic underlying lung disease because of the risk of bronchospasm.
- Monitor patients with glaucoma for increased intraocular pressure.
- Abnormalities in laboratory tests may include elevations of liver function tests
 (e.g., alkaline phosphatase, AST, ALT, lactic dehydrogenase, bilirubin), blood
 urea nitrogen, hemolytic anemia, and positive direct antibody test. Increased
 levels of catecholamines and their metabolites in plasma and urine may result
 in false-positive results suggesting pheochromocytoma.
- The most common adverse reactions (≥ 5% and > placebo) were cough (15% vs 2%), upper respiratory tract infection (6% vs 3%), nausea (5% vs 3%), and sputum discolored (5% vs 0%).
- Use of selective MAO-B inhibitors with INBRIJA may be associated with orthostatic hypotension. Monitor patients taking these drugs concurrently.
- Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce levodopa efficacy; monitor for worsening symptoms.
- Iron salts or multivitamins with iron salts may reduce levodopa bioavailability.
- INBRIJA should be used during pregnancy/nursing only if potential benefit
 justifies potential risk. There are no adequate data on INBRIJA in pregnant
 women or breastfed infants. Animal data shows carbidopa/levodopa is
 developmentally toxic (including teratogenicity). Levodopa may affect milk
 production, interfering with lactation. Levodopa has been detected in human milk.
- Safety and effectiveness in pediatric patients have not been established.
- Geriatric patients (n=56) experienced more of the following adverse reactions than patients <65 (n=58): cough (25% vs 5%), upper respiratory tract infection (11% vs 2%), nausea (7% vs 3%), vomiting (4% vs 2%), pain in extremities (4% vs 0%), and discolored nasal discharge (4% vs 0%).

Please see Full Prescribing Information available at www.inbrija.com/prescribing-information.pdf



INBRIJA® PRESCRIPTION REQUEST FORM

Fax completed form to: 1 855-886-2484

For assistance please call Prescription Support Services at: 1 888-887-3447

Patient Authorization

By signing this authorization, I authorize my health plans, physicians, and pharmacies (collectively, my "Providers") to disclose my personal health information relating to my medical condition, treatment, care management, and health insurance, as well as information provided on this form and any prescription (collectively, "Personal Health Information"), to Acorda Therapeutics, Inc. ("Acorda"), its representatives, agents, and contractors, and Acorda's Inbrija Prescription Support Services hub (collectively "the Entities") for purposes of (1) providing services to me by Prescription Support Services; (2) facilitating the provision of products, supplies or services by Acorda; (3) registering me in any applicable Acorda product registration program; (4) evaluating the effectiveness of Acorda's INBRIJA education programs; (5) enrolling me in Acorda's patient assistance program, copay mitigation program, or similar programs which may be deployed by Acorda (if one or more such programs apply to me); and (6) to facilitate the provision of information and training to me by third parties regarding the use of INBRIJA and its inhaler device. I understand that my pharmacies will disclose to the Entities certain personal health information regarding the dispensing of my INBRIJA prescription and that such disclosure will result in remuneration to my pharmacies. I understand that once my Personal Health Information is disclosed to the Entities under this authorization, it is no longer protected by Federal privacy laws and may be further disclosed by the Entities. I understand that I may refuse to sign this authorization and that my healthcare provider(s) and health plan(s) will not condition my treatment or benefits on whether I sign this Patient Authorization. I understand, however, that if I do not sign this authorization, I may not be able to receive assistance through Prescription Support Services. I understand that I am entitled to a copy of this authorization.

I understand that I may cancel this authorization at any time by mailing a letter requesting such cancellation to Acorda Therapeutics, Inc., P.O. Box 15938, Newport, Beach, CA 92659 but that this cancellation will not apply to any information already used or disclosed pursuant to this authorization before notice of the cancellation is received by each of the Entities. This authorization expires ten (10) years from the date of execution or upon such earlier date as may be mandated by state law, if applicable.

Patient Marketing Consent

I authorize the release of information provided in this enrollment form to Acorda Therapeutics, Inc. ("Acorda") for the provision of education, training, and ongoing support on the use of INBRIJA and other products and services. Acorda may provide me with educational or product related informational materials. Acorda's contracted business partners and/or their affiliates, which operate Acorda's Prescription Support Services hub for Acorda, may receive compensation from Acorda for providing such services and information. I authorize Acorda and its business partners to contact me with promotional materials related to my treatment, to use and disclose my information in order to send me information or materials related to INBRIJA or any other related products or services, to contact me occasionally to obtain feedback (for market research purposes) about Acorda, INBRIJA, or Prescription Support Services, to operate (and improve the quality of) the INBRIJA program, or otherwise as required or permitted by law. If I do not wish to receive information related to INBRIJA or any related products or services or to be contacted occasionally for market research purposes, I understand that I may call Prescription Support Services toll-free number, 1 888-887-3447 at any time to opt out from these communications.

WHAT YOU SHOULD EXPECT NEXT

PRESCRIPTION SUPPORT SERVICES
CALLS PATIENT DIRECTLY



After determining coverage, a specialist will call you to:

- Review coverage and financial assistance options (if eligible)
- Ensure you know how to use INBRIJA
- Tell you which specialty pharmacy will handle your prescription

You must speak to the specialist who calls to obtain this information. Calls from the Prescription Support Services specialist will come from the phone number 1 888–887–3447.

2 SPECIALTY PHARMACY DELIVERY OF INBRIJA



- A specialty pharmacy representative will call you to arrange payment details and delivery of INBRIJA
- The specialty pharmacy will follow up with refills as prescribed

You must speak to the specialty pharmacy representative who calls to confirm your shipment. Calls may be from an unrecognized phone number.

QUESTIONS?

Call Prescription Support Services toll free 1 888-887-3447

Mon-Fri 8:00am - 8:00pm ET